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Highlights 19 
x Positive association of arsenic exposure and skin lesions with labour occupations. 20 
x Significant dose response relationship between arsenic exposure and skin lesions.  21 
x Inefficient arsenic methylation capacity significantly associated with skin leisons.   22 
x Variability in 20 houses, 28 persons with and 25 persons without skin problems. 23 
Abstract 24 
This study was conducted in rural Pakistan to assess the dose-response relationship 25 
between skin lesions and arsenic exposure and their variation by demographic 26 
characteristics. The study included 398 participants (66 participants with skin lesions 27 
and 332 without) residing in six previously unstudied villages exposed to ground 28 
water arsenic in the range of <1 to 3090 µg L-1. The skin lesions identification 29 
process involved interview and physical examinations of participants followed by 30 
confirmation by a physician according to UNICEF criteria. Urinary inorganic arsenic 31 
(iAs), total arsenic (tAs), monomethylarsonic acid (MMA), and dimethylarsinic acid 32 
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(DMA) were analysed to determine methylation capacity, methylation efficiency and 33 
the dose-response relationship with skin lesions. Study participants with skin lesions 34 
were found to be exposed to arsenic >10 µg L-1 with a daily arsenic intake of 35 
3.23±3.75 mg day-1 from household ground water sources for an exposure duration 36 
of 10-20 years. The participants with skin lesions compared to those without skin 37 
lesions showed higher levels of urinary iAs (133.40 ± 242.48 vs. 44.24 ± 86.48 ȝJJ-1 38 
Cr), MMA (106.38 ± 135.04 vs. 35.43 ± 39.97 ȝJ J-1 Cr), MMA% (15.26 ± 6.31 39 
vs.12.11 ± 4.68) and lower levels of DMA% (66.99 ± 13.59 vs. 73.39 ± 10.44) and 40 
secondary methylation index (SMI) (0.81 ± 0.11 vs. 0.86 ± 0.07). Study participants 41 
carrying a lower methylation capacity characterized by higher MMA% (OR 5.06, 95% 42 
CI: 2.09-12.27), lower DMA% (OR 0.64, 95% CI: 0.33-1.26), primary methylation 43 
index (PMI) (OR 0.56, 95% CI: 0.28-1.12) and SMI (OR 0.43, 95% CI: 0.21-0.88) 44 
had a significantly higher risk of skin lesions compared to their corresponding 45 
references after adjusting for occupation categories. The findings confirmed that 46 
inefficient arsenic methylation capacity was significantly associated with increased 47 
skin lesion risks and the effect might be modified by labour intensive occupations. 48 
 49 
Keywords: Arsenicosis, skin lesions, hyperpigmentation, keratosis, 50 
monomethylarsonic acid (MMA), methylation capacity. 51 
  52 
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1. Introduction  53 
Arsenic (As) exposure from drinking water has placed about 200 million people 54 
worldwide at risk of arsenic induced health hazards (National Research Council, 55 
2001). Epidemiological studies have revealed the associations between arsenic 56 
exposure and multiple health effects. These include developmental effects, 57 
neurotoxicity, diabetes, pulmonary disease and cardiovascular disease (Agency for 58 
Toxic Substances and Disease Registry, 2007). Arsenic is a recognized carcinogen 59 
causing cancer of the skin, liver, lung, kidney, prostate and bladder (International 60 
Agency for Research on Cancer, 2012; Mendez et al., 2017; Hong et al., 2014). Skin 61 
lesions are a typical sign of arsenic toxicity appearing after a persistent arsenic 62 
ingestion for 5-10 years (Lien et al., 1999; Guha Mazumder et al., 1998). There is 63 
considerable evidence of the prevalence of arsenical skin lesions in Bangladesh 64 
(Ahsan et al., 2006), India (Guha Mazumder et al., 1998),  Mongolia and China (Sun, 65 
2004).  66 
Inorganic arsenic (iAs) ingested from drinking water is metabolized in the human 67 
body first by its methylation to monomethylarsonic acid (MMA) and then to 68 
dimethylarsinic acid (DMA), resulting in iAs excretion from the body as MMA and 69 
DMA (Vahter, 2002). Earlier studies have revealed the relationship between urinary 70 
arsenic metabolites and arsenic induced skin disorders (Lindberg et al., 2008; Kile et 71 
al., 2011). However, the individuals within the same region or population may have 72 
different urinary arsenic levels and methylation capacity even when exposed to the 73 
same level of arsenic (Vahter, 1999). This suggests there may be variable disease 74 
susceptibility among the exposed persons within a population. Nevertheless, the 75 
associations between inadequate arsenic methylation capacity and arsenic-induced 76 
health effects may be further influenced by demographic and socio-economic 77 
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features, inter-individual variability, genetic or geographical variations (Chen et al., 78 
2013; Lindberg et al., 2010; Steinmaus et al., 2006). 79 
Earlier studies in Pakistan (Fatmi et al., 2013; Fatmi et al., 2009; Ahmed et al., 2014) 80 
have assessed the association between water and/or urinary iAs concentrations and 81 
the prevalence of skin lesions. This investigation focused on the influence of urinary 82 
arsenic metabolites and arsenic methylation capacity on disease susceptibility which 83 
is, as yet, unstudied. The prevalence of arsenic related skin manifestations had not 84 
been scientifically investigated in this study population and hence evaluated as a 85 
biological marker of individual exposure.  Moreover, to address the arsenic mitigation 86 
challenges, identifying the risk groups in the population of arsenic affected regions is 87 
also required (National Research Council, 2001; Jakariya et al., 2005).  88 
 89 
2. Methodology 90 
2.1  Study Design and population 91 
The present work is a cross-sectional study involving individuals exposed to arsenic 92 
from six villages in the districts of Kasur, Sahiwal, Bahawalpur and Rahim Yar Khan, 93 
Pakistan. Our previous study showed that drinking water was the primary source of 94 
arsenic exposure beyond the WHO provisional guideline value (10 ȝJ /í) in the 95 
selected villages (Rasheed et al., 2017a). Selection of sample size, recruitment of 96 
study participants and demographic characteristics have been published elsewhere 97 
(Rasheed et al., 2017b). The 398 non-smoking participants recruited had lived in the 98 
study villages for the last 5 years and children (<5 years) by birth and provided 99 
consent to being interviewed and physically examined. Health care services in these 100 
rural settings were not well organized and no systematic patient records were 101 
available to track their arsenic related medical history.  102 
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2.2  Physical examination of skin 103 
Initially, study participants were observed and interviewed at their houses by the 104 
trained non-physician health workers to record observations on general health status 105 
and to specifically screen the individuals with cutaneous signs of skin lesions. Unlike 106 
skin cancer, which takes decades to develop, these lesions can appear within a few 107 
years of exposure and usually progress through stages. The diagnostic guidelines of 108 
the UNICEF clinical diagnostic manual (Sun Guifan et al., 2004) were followed in this 109 
screening process. The interviewers, unaware of the health status of the participants, 110 
interviewed them using a structured questionnaire that collected information on 111 
general wellbeing and visible skin lesions were digitally photographed without facial 112 
identification.  113 
Following the steps indicated in Figure-1, initially screened individuals (n=80) were 114 
re-examined after a week at the basic health unit (BHU) of each village by a 115 
physician with expertise in detection and diagnosis of skin lesions. In accordance 116 
with the earlier mentioned diagnostic guidelines (Sun Guifan et al., 2004), 117 
hyperpigmentation was symptomized as raindropǦlike spots, diffused dark brown 118 
spots or darkening of the skin on the limbs or chest, back, and abdomen. Keratosis 119 
was identified as thickening of the skin of the palms of hands or the soles of feet, or 120 
small flanges (0.4 to 1 cm in diameter) emerged as small corn-like elevations on 121 
palms and soles. 122 
Initially screened individuals were physically examined to ascertain the presence, 123 
shape and location of visible skin lesions. Out of 80 individuals initially screened as 124 
patients, 14 cases were confirmed as not having arsenic induced skin lesions. Thus, 125 
the study population was grouped into two subgroups including participants with 126 
arsenic specific skin lesions (n=66) and those without such skin lesions (n=332).  127 
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2.3   Measurement of Urinary Arsenic Metabolites 128 
The spot urine samples were collected from all participants in a labelled sterile 2 oz 129 
polyethylene urine collection container and kept in an ice box for three hours. Exactly 130 
1 mL of urine was kept separately for creatinine (Cr) determination. All urine samples 131 
were then immediately transferred to the 1DWLRQDO :DWHU 4XDOLW\ /DERUDWRU\ DW í132 
°C, where creatinine was determined. All samples were t hen shipped with dry ice to 133 
the Brooks Applied Laboratory (BAL), USA E\ DLU DQG VWRUHG DWí&DQGILQDOO\134 
measured for urinary arsenic metabolites within 4 months. Three of the study 135 
participants did not provide their urine samples. In total, 395 samples were collected, 136 
as well as field duplicates (4% of samples, n=15). Due to spillage during 137 
transportation, ten samples did not have enough volume for arsenic speciation. 138 
Thus, the Brooks Applied Laboratory (BAL) received 395 samples for total arsenic 139 
and 385 samples for arsenic speciation. Urinary creatinine concentration was 140 
measured by means of the kinetic Jaffe method using a colorimetric auto-analyzer 141 
(Hitachi Ltd., Tokyo, Japan) based on the reaction between creatinine and alkaline 142 
picrate (Bonsnes and Taussky, 1945). Concentrations of urinary arsenic species 143 
were adjusted using urinary creatinine to correct for variable water excretion rates 144 
at the time of specimen collection (Barr et al., 2005). This adjustment was done by 145 
dividing the concentration of arsenic metabolites (ȝJ L-1) by U-Cre (g L-1) to express 146 
urinary arsenical species as ȝJJ-1 creatinine. Frozen urine samples were thawed to 147 
room temperature and centrifuged at 3000 rpm for 10 min and the resultant 148 
supernatants were used for arsenic analysis. The supernatants were diluted 10-fold 149 
with ultrapure water and analyzed. Total arsenic was measured using inductively 150 
coupled-plasma dynamic reaction cell-mass spectrometry (ICP-DRC-MS) on a ELAN 151 
DRC II ICPMS (Perkin Elmer SCIEX, Concord, Ontario, Canada) following U.S. 152 
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Environmental Protection Agency method 1638 mod. (U.S. Environmental Protection 153 
Agency, 1996). Urinary arsenic speciation i.e. arsenate (AsV), arsenite (AsIII), 154 
monomethylarsonic acid (MMA), dimethylarsinic acid (DMA) and arsenobetaine 155 
(AsB) were measured on an anion-exchange high-performance liquid 156 
chromatography system (Dionex GP-40) coupled to an inductively coupled plasma ± 157 
mass spectrometer (ICP-MS) (Agilent 7700x ICPMS, Agilent Technologies) following 158 
the proprietary BAL method. Aqueous samples were filtered through a 0.45-µm filter 159 
and an aliquot injected onto an anion-exchange column. Measures used to ensure 160 
appropriate preservation of MMA and DMA species in urine samples included 161 
sample preservation and preparation at low temperatures, immediate freezing upon 162 
collection, least sample treatment before analysis, and rapid speciation when 163 
analysed. Whilst As(III) can oxidize to As(V) during sample transport, storage, and 164 
preparation, these are expressed as total iAs (i.e. As(III)+As(V). The limits of 165 
detection were 0.1 µg L-1 for tAs, As(III), DMA, and AsB, 0.3 µg L-1 for As(V) and 0.2 166 
µg L-1 for MMA.  167 
The proportions of urinary arsenic metabolites (iAs%, MMA% and DMA%) and 168 
methylation indices, the primary methylation index (PMI) and secondary methylation 169 
index (SMI) were calculated to reflect the arsenic methylation capacity. The arsenic 170 
methylation indices were defined as the percentages of iAs%, MMA% and DMA%, 171 
calculated by dividing the concentration of each species by the sum of iAs, MMA 172 
and DMA. The PMI was calculated as the ratio between MMA+DMA and tAs 173 
(equation-1), and the SMI as the ratio between DMA and MMA+DMA (equation-2), 174 
(Sun et al., 2007).  175 
 176 
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 ܲܯܫ ൌ ܯܯܣ ൅ ܦܯܣݐܣݏ  (1) 
 177 
 ܵܯܫ ൌ  ܦܯܣሺܯܯܣ ൅ ܦܯܣሻ (2) 
 178 
Quality assurance of urinary arsenic species data was provided by the analysis of 179 
NIST (National Institute of Standards and Technology) traceable standard reference 180 
materials (SRMs-1640A, trace elements in natural water). Background 181 
contamination was monitored using laboratory fortified blanks for urine analysis. 182 
Duplicate measurements were made on 10% (n(? (? RI XULQH VDPSOHV IRU WRWDO183 
arsenic and arsenic species (Table-1). The reliability of the arsenic species 184 
determination was evaluated by analysing samples in duplicate and spiking the 185 
samples with AsIII, AsV, MMA, DMA and AsB. Data quality in terms of precision, 186 
accuracy, method reporting limits (MRLs), method detection limits (MDLs) and 187 
FRPSOHWHQHVVPHW WKHFULWHULDHVWDEOLVKHG LQ WKH%$/¶VTXDOLW\DVVXUDQFHSURMHFWSODQ188 
(QAPP), i.e. relative percent difference (RPD) of <25%, percent recovery of 75 to 189 
125% and completeness of 80%. Field duplicates for urine indicated mean 190 
percentage differences of IRU W$V00$DQG'0$ (Supplementary Information: 191 
Table SI-1). 192 
2.4  Individual exposure assessment 193 
All household ground water samples were collected at the houses of study 194 
participants from six selected villages during June-September, 2014 after the skin 195 
lesions examinations. These were analysed for total arsenic using USEPA method 196 
200.8 (U.S. Environmental Protection Agency, 2008) and arsenic species by the 197 
Brooks Applied Laboratory using ion chromatography inductively coupled plasma 198 
collision reaction cell mass spectrometry (BAL proprietary method). These data were 199 
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published previously (Rasheed et al., 2017a). Daily arsenic intake (mg day-1) was 200 
calculated by multiplying tKH KRXVHKROG JURXQG ZDWHU DUVHQLF FRQFHQWUDWLRQ ȝJ /-1) 201 
by the daily water intake from the household ground water source (L day-1). Thus, 202 
exposure in this study was assessed using urinary arsenic metabolites and tAs of 203 
household ground water. In order to reduce the potential bias, the participants and 204 
health examiners were unaware of the individual arsenic levels of water samples 205 
collected from household ground water sources which were analysed after 206 
completion of the survey.  207 
2.5  Covariates 208 
In addition to the primary exposure variable we evaluated other covariates suspected 209 
to be associated with arsenic exposure. These covariates included socio-210 
demographic factors i.e. age, sex, body weight, exposure duration, daily water 211 
intake, villages and occupation, and were derived from the questionnaire based 212 
interviews with study participants, published previously in (Rasheed et al., 2017b). 213 
2.6  Statistical Analysis 214 
Since the urinary arsenic metabolites data had a positively skewed distribution, 215 
natural logarithmic transformations were used to normalize their distributions and the 216 
means as well as the 95% confidence interval (CI). Mean arsenic concentrations in 217 
urine and household ground water were calculated for participants with and without 218 
skin lesions. The Student t test and Chi-square test was used to assess the 219 
differences of exposure variables between participants with and without skin lesions. 220 
Urinary arsenic metabolites and methylation indices were stratified into quartiles (0-221 
25%, 25-50%, 50-75% and 75-100%) when estimating the odd ratios (ORs) for 222 
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having skin lesions. Variables measured on a continuous scale, including age, body 223 
weight, daily arsenic intake and arsenic exposure, were categorized to evaluate risk.  224 
Univariate and multivariate logistic regression analyses were used to evaluate the 225 
effect of increasing levels of arsenic intake from water, urinary arsenic metabolites 226 
and urinary arsenic methylation indices on the risk of skin lesions. The results of 227 
logistic analyses were presented as ORs along with their 95% CIs. Only covariates 228 
revealed to be significant in the univariate logistic regression and factors of interest 229 
were included in the multivariate regression analysis. We used a p value of <0.05 for 230 
statistical significance. Microsoft Excel and SPSS 17.0 (IBM, New York, NY, USA) 231 
were used for the statistical analysis.  232 
 233 
3. Results  234 
3.1  Characteristics of the study population 235 
The baseline characteristics of all participants by status of skin lesions are given in 236 
Table 1. The age, body weight, daily water intake, tAs in household water sources 237 
and daily water intake were higher among participants with skin lesions than those 238 
without skin lesions. Urinary arsenic metabolites such as tAs, iAs, MMA and DMA 239 
were higher in participants with skin lesions than those without skin lesions. AsB, 240 
excreted as a result of seafood ingestion, was not detected in this study population. 241 
Participants with skin lesions also possessed higher means for urinary iAs%, 242 
MMA%, lower urinary DMA% and lower PMI and SMI compared with participants 243 
without skin lesions (Table 1).  244 
   245 
The distribution of cutaneous signs observed in the study participants (Figure 2) 246 
varied; hypopigmentation (9.5%), hyperpigmentation (23.8%), hypo and/or 247 
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hyperpigmentation (6.3%), melanosis (7.9%), whilst keratosis/hyperkeratosis on the 248 
palm or sole was the most prevalent cutaneous sign of arsenicism (47.6%). 249 
 250 
3.2  Association between Urinary Arsenic Methylation Indices and Skin lesions 251 
Table 2 shows the distribution of subgroups with and without skin lesions by sex, 252 
age, daily arsenic intake, villages, body weight and occupation. Males were more 253 
likely than females to have skin lesions (OR 1.90, 95% CI: 1.05-3.45). Compared 254 
with the participants in the youngest age group (6 years), the risk of skin lesions 255 
increased nearly threefold for participants in the oldest age group >16 years as 256 
indicated by an OR of 3.56 (95% CI: 1.25-10.15).  257 
There were no skin problems among participants exposed to ground water tAs levels 258 
<10 µg L-1. The association between tAs in water and skin lesion (Table 2) showed a 259 
significant increasing linear trend from 10-50 µg L-1 (OR 1.00: reference) to >50-100 260 
µg L-1 (OR 23.4, 95% CI: 3.06-178.68) and >100 µg L-1 (OR 219, 95% CI: 29.14-261 
1645.70). Consequently, the OR estimates also increased significantly (p<0.001) 262 
with increasing arsenic intake (0.001-11.773 mg day-1). Risk was significantly higher 263 
for the subgroup in the upper quartile of daily arsenic intake (OR 126, 95% CI: 16.89-264 
939.46) suggesting a dose response effect of arsenic exposure from drinking water 265 
intake (Table 2).   266 
A direct association was found between body weight and skin lesion risk (p=0.016), 267 
with a threefold increase with increasing body weight >35 kg (OR 3.63, 95% CI 268 
1.273-10.35). Based on the socioeconomic situation, intensity of physical and 269 
outdoor activities, and occupations of the study participants they were divided into 270 
labour intensive (farmers, wives of farmers and service providers like security 271 
guards, drivers etc.) and non-labour intensive subgroups (non-working house wives, 272 
students, tailors, teachers and un-employed). The labour intensive category 273 
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indicated a higher risk of skin lesions (OR 2.83, 95% CI: 1.48-5.39). At village level, 274 
a significant increase in the prevalence of skin lesions was found in arsenic affected 275 
villages (Table 2), with the highest prevalence of 67.7% skin lesion in Badarpur (OR 276 
20.31, 95% CI: 7.04-58.57), where 95.8% of hand pumps were contaminated with 277 
arsenic.  278 
ORs for association of urinary arsenic metabolites with the risk of skin lesions using 279 
multiple logistic regression analysis after adjustment for confounding factors, such as 280 
age, sex, daily arsenic intake, villages, body weight and occupation, were 281 
determined. A higher degree of effect was found when adjusting with occupational 282 
categories, as presented in Table 3. After adjustment for occupation, a significantly 283 
higher skin lesion risk was found in the third (OR 6.35, 95% CI: 2.08-19.44; p = 284 
0.001) and fourth quartiles (OR 13.07, 95% CI: 4.30-39.68; p = 0.000) of urinary tAs. 285 
A significantly increased risk was found for participants in 4th quartiles of urinary iAs 286 
(OR 5.61, 95% CI: 2.48-12.70; p = 0.000) Similarly, a significantly increased risk was 287 
found in the 4th quartile of MMA (OR 5.83, 95% CI: 2.57-13.24; p = 0.000). The 3rd 288 
and 4th quartiles of urinary DMA showed significantly higher ORs for skin lesions 289 
(Table 3). 290 
Participants with the highest urinary iAs% (OR 2.65, 95% CI: 1.22-5.75) and MMA% 291 
(OR 5.06, 95% CI: 2.09-12.27) showed a significantly highest risk of skin lesions as 292 
compared to their reference quartiles (Table 4). Participants in the 2nd  quartiles (OR 293 
0.64, 95% CI: 0.33-1.26) of urinary DMA% showed a significantly higher risk of skin 294 
lesions as compared to their reference quartiles before and after adjustment for 295 
YLOODJHU¶V RFFXSDWLRQV. A significant increased risk of skin lesions was detected in 296 
participants in the 2nd quartile of PMI (OR 0.56, 95% CI: 0.28-1.12) and SMI (OR 297 
0.43, 95% CI: 0.21-0.88) both before and after adjustment (Table 4).  298 
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4. Discussion 299 
This was the first cross sectional study to evaluate the dose±response relationship 300 
between arsenic exposure and skin lesions in rural Pakistan. Epidemiologic 301 
outcomes suggest that arsenic induced skin lesions although non-cancerous may 302 
convert to be cancerous with prolonged arsenic exposure (Haque et al., 2003; 303 
International Agency for Research on Cancer, 2004; National Research Council, 304 
2001). Human methylation capacity plays an important role in determining arsenic 305 
induced disease susceptibility. It is therefore important to assess not only the arsenic 306 
methylation indices, but also the aggregated effect of these indices with population 307 
specific potential modifiers on arsenic-related disease risk. The population in the 308 
study villages was found mainly to be exposed to iAs (<1 to 3090 µg L-1) from their 309 
household ground water sources. More than 89% of the household hand pumps 310 
exceeded the WHO provisional guideline value for arsenic in drinking water (10 ȝJ311 
Lí1), whilst 56% were also IRXQGWRKDYH L$VDERYH3DNLVWDQ¶VZDWHUTXDOLW\VWDQGDUG312 
for arsenic (50 µg L-1) (Rasheed et al., 2017a). The distribution of skin lesions 313 
indicated a lowest prevalence (0.7%) at 10-50 µg L-1, 13.8% at 50-100 µg L-1 and 314 
60% at >100 µg L-1.Consequently, a higher prevalence of skin lesions was also 315 
found for those with higher daily arsenic intake. Past studies have reported the 316 
prevalence of skin lesions at iAs concentrations of <10 ȝJ/í1 in China (Yang et al., 317 
2017) and Bangladesh (Ahsan et al., 2006; Argos et al., 2011). Despite a very high 318 
arsenic exposure level for the current study population, the prevalence rate of skin 319 
lesions was found to be lower than the 22% reported in three villages of rural 320 
Bangladesh (Ahsan et al., 2000). Similarly, 41.8% was reported in Inner Mongolia for 321 
a population  with an arsenic exposure level of 2.3-197.3 ȝJ /í1 (Guo et al., 2006). 322 
Various demographic and life style factors affect arsenic methylation in arsenic-323 
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exposed populations such as age, sex, ethnicity, genetics, socioeconomic status, 324 
smoking, alcohol drinking, exposure route and duration, arsenic species, and 325 
nutritional inadequacy for essential vitamins, folate, N-acetylcysteine, glutathione, 326 
and zinc (Hsueh et al., 2016). The association between skin lesions risk and 327 
demographic characteristics was evaluated using univariate logistic regression. Age, 328 
sex, daily arsenic intake, village location, body weight and occupation were revealed 329 
to be significant factors. A significantly higher prevalence of arsenic induced skin 330 
lesions in males (19.7%) than females (11.4%) suggests a higher susceptibility of 331 
males to develop skin lesions. These findings are consistent with other studies 332 
conducted in Bangladesh and elsewhere (Vahter et al., 1995; Argos et al., 2011; 333 
Rahman et al., 2006). The lower prevalence of skin lesions in female participants 334 
underscores the better methylation tendency of women than men, possibly linked 335 
with biological (hormones, physiology, genetics) and physical or social (sun 336 
exposure, water intake and smoking habits) differences between men and women.  337 
Significantly increased skin lesions risk was found among older participants (>16 338 
years) with an OR of 3.56 (95% CI: 1.25-10.152) compared to those 6 years. The 339 
probable reasons for higher age related susceptibility to arsenic-induced skin lesions 340 
include longer exposure duration, higher sun exposure due to the nature of 341 
occupation and daily water intake. Also, lower enzymatic and hormonal activity which 342 
are involved in arsenic detoxification, and old age related nutritional inadequacy and 343 
lower immunity may be the potential factors (Ahsan et al., 2006; Haque et al., 2003; 344 
Wei, 1998; Ahsan et al., 2007). Exposure duration to tAs from drinking water by 345 
participants with skin lesions varied  between 10-20 years (tAs >100 µg L-1), 14-20 346 
years (As 50-100 µg L-1) and 20 years for (As 10-50 µg L-1) on the basis of 347 
consumption duration for household ground water. This suggests that the affected 348 
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populations would be consuming untreated ground water for several years. Ground 349 
water tAs being the direct exposure variable seems to indicate the clear dose related 350 
trend for skin lesions risk above >10 ȝJ/í. This is indicated by 20% increased risk 351 
of skin lesions for those exposed to 50±100 ȝJ/í iAs compared to those with <10 352 
ȝJ /í, and this risk further increased more than 9.5-fold (OR 219, 29.14-1645.7) for 353 
the exposure >100 µg L-1 (Table 2). 354 
The study showed that male, older, and/or heavier participants were more likely to 355 
be at risk of arsenic exposure (Table 2). An increased risk of skin lesions (OR 2.83, 356 
95% CI: 1.48-5.39) was found among participants involved in labour intensive 357 
(farmers, wives of farmers and service providers like security guards, drivers etc.) 358 
occupations compared to the non-labour intensive (non-working house wives, 359 
students, tailors, teachers and un-employed) occupations (Table 2). Occupationally, 360 
the majority of the study participants were farmers (n=186) working outdoors and 361 
generally had sun exposure for 8-10 hours per day. The labour intensive occupations 362 
also included wives of farmers (n=56) contributing in the crop fields with their farmer 363 
husbands, possibly having higher sun exposure resulting in higher drinking water 364 
intake. The labour intensive occupations may also be associated with other risk 365 
enhancing factors such as low socio-economic status and poverty related 366 
malnutrition.  367 
Simultaneous adjustment of significant confounding factors (Table 2) in multivariate 368 
regression analysis has showed an overall model significance for YLOODJHU¶V369 
occupation and thus adjustments were made for labour intensive and non-labour 370 
intensive occupation categories. This model adjustment was utilized to show that the 371 
association between skin lesions and urinary arsenic metabolites (tAs, iAs, MMA, 372 
DMA), methylation capacity (iAs%, MMA%, DMA%) and methylation efficiency (PMI 373 
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and SMI) might be enhanced by intensive physical activities and higher sun 374 
exposure.  375 
The influence of occupation is obvious from the decrease in adjusted ORs than 376 
unadjusted ORs for methylation capacity and efficiency indicators. Contrary to the 377 
studies by Haque et al. (2003) indicating ORs of 3.1 (51-99 ȝJ/í), and 5.0 (>150 ȝJ378 
Lí), and (Guo et al., 2006) showing ORs of 15.50 (51-99 ȝJ/í), and 25.70 (>150 379 
ȝJ /í), this study showed much higher ORs of arsenical skin lesions for increasing 380 
arsenic exposure from household water sources. The impact of metabolically 381 
produced arsenic on the significantly increased skin lesions risk was obvious among 382 
the skin lesions subgroup in the 4th quartiles of urinary tAs, iAs, MMA, DMA, iAs% 383 
and MMA%, 2nd quartiles of DMA%, PMI and SMI.  384 
A significantly increasing trend was found with increasing levels of urinary tAs (>247 385 
ȝJJí) indicated by a 2.4-fold increased odds of skin lesions (Table 3). Compared to 386 
this, Argos et al. (2011) reported 2.4-fold increased odds of skin lesions at a 387 
comparatively higher level of urinary tAs (i.e. ! ȝJgí). Intermediary by-products 388 
of iAs such as MMA and DMA are methylated via similar metabolic pathways, 389 
however MMA is considered more toxic than iAs and DMA (Chen et al. (2013). The 390 
trivalent forms of MMA produced in this process were considered to be more toxic 391 
than pentavalent MMA (Hirano et al., 2003; Petrick et al., 2001). The limited 392 
evidence on the health risk potential of ingested arsenic compared to metabolically 393 
produced MMA or DMA has given impetus to assess the relationship between 394 
arsenic related health effects and methylation capacity. Following this, the study 395 
results showed the association of daily arsenic intake with skin lesions incidence in a 396 
dose-dependent manner for absolute concentrations of urinary arsenic metabolites 397 
(Table 3). Increasing ORs from lower to upper quartiles of urinary arsenic 398 
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metabolites demonstrated that the magnitude of exposure is directly related to the 399 
presence of skin lesions. Sub-groups with skin lesions indicated significantly higher 400 
mean values of urinary iAs%, MMA%, lower DMA%, PMI and SMI compared to 401 
those without skin lesions (Table 1). These findings are also in close agreement with 402 
the studies by Steinmaus et al. (2006) and Kile et al. (2011), revealing higher levels 403 
of urinary MMA% related with the higher risk of lung cancer and skin lesions 404 
respectively. 405 
Arsenic methylation mechanisms are still controversial, however the ORs for arsenic 406 
induced diseases have been found higher in those with higher MMA% (Chen et al., 407 
2013; Zhang et al., 2014; Li et al., 2015). Of all the methylation indices determined in 408 
this study, MMA% in upper quartiles (OR 5.06, 95% CI: 2.09-12.27) indicated the 409 
highest skin lesions risk compared to its corresponding reference (OR 1.00). 410 
Comparing the current study findings with earlier studies, MMA% is suggested to be 411 
an underlying reason of higher dermatoxicity and also a potential biomarker for 412 
preliminary screening of individuals suspected to be at an arsenic induced health 413 
risk.  414 
The significantly decreased risk of skin lesions in the fourth quartiles of DMA% (OR 415 
0.22, 95% CI: 0.10-0.50) and SMI (OR 0.17, 95% CI: 0.07-0.40) was also in 416 
agreement with earlier studies on arsenic induced development delays (Hsieh et al., 417 
2014) and skin lesions (Li et al., 2011). The higher iAs%, MMA% and lower DMA% 418 
among the participants with skin lesions depicted inefficient methylation capacity 419 
compared to those without skin lesions. This association between inadequate 420 
methylation capacity and arsenic induced health effects was found to be consistent 421 
with studies on arsenic induced cardiovascular diseases (Chen et al., 2013; Li et al., 422 
2015) and bladder cancer (Chen et al., 2003).  423 
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Participants with oral arsenic exposure >50 ȝJ /í and also having skin lesions 424 
showed significant increased (p=0.004) urinary MMA concentration compared to 425 
those exposed to tAs through drinking water but without skin lesions. The study 426 
participants identified with skin lesions belonged to 47 households. Out of these 47, 427 
20 houses comprising 53 study participants revealed 28 persons with skin lesions, 428 
while 25 persons from the same houses showed no skin problems, despite being 429 
exposed to the same level of arsenic from their household water sources (Figure 3).  430 
Persons within the same house with higher arsenic concentration but with no skin 431 
lesions were found to be younger in age than their family members having skin 432 
lesions. The fact that some study participants did not develop skin lesions despite 433 
similar exposure to arsenic as those who did suggests the possible influence of inter-434 
individual variability and various demographic, biological, genetic and nutritional 435 
factors on methylation efficiency. Valenzuela et al. (2009) found that 436 
genetic polymorphisms for arsenic (+3 oxidation state) methyltransferase (AS3MT) 437 
influence the susceptibility of humans to arsenical skin lesions and these people 438 
might be at higher risk for other arsenic induced adverse health effects. Deficiency of 439 
nutrients such as proteins, folate, vitamin B12 and vitamin B6 have been emphasized 440 
to interfere in arsenic metabolism and toxicity resulting in increased susceptibility to 441 
arsenic induced disease e.g. age-adjusted prevalence keratosis (Zablotska et al., 442 
2008). This is indicated by positive correlation between urinary DMA and plasma 443 
folate in Bangladesh (Gamble et al., 2005) and negative correlation between the 444 
prevalence of arsenic-induced skin lesions and proteins intake (Mitra et al., 2004). 445 
Nutritional inadequacy may also be the reason for age related susceptibility to skin 446 
lesions, especially in case of older participants. The individuals with or without skin 447 
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lesions might have suffered from other arsenic related health hazards which need to 448 
be further investigated. 449 
The study findings may prove useful in understanding arsenic induced susceptibility 450 
to skin lesions, for early detection of skin lesions in communities residing in arsenic-451 
affected regions, and may also be helpful for policy and decision makers. In addition 452 
to speciation for MMA, future studies should also evaluate the impact of association 453 
between arsenic methylation capacity and other modifiable risk factors on the 454 
variations in arsenic induced health hazards.  455 
 456 
5. Conclusions 457 
The occupation adjusted odd ratios suggested a significant dose response 458 
relationship between various exposure levels measured, using either water or urinary 459 
total arsenic, and the risk of skin lesions. The study supports the findings of other 460 
cross sectional studies demonstrating the inefficient methylation capacity in 461 
association with higher iAs% and MMA%, lower DMA%, PMI and SMI among 462 
individuals affected with arsenic induced diseases. The significantly increased risk of 463 
MMA% in older individuals with skin lesions indicates the metabolic barriers to 464 
converting MMA to DMA, also underscoring the probability of other arsenic induced 465 
health hazards among the exposed population. Even though skin lesions occur at 466 
exposure to 10-50 µg L-1 arsenic, countries including Pakistan currently follow a 467 
drinking water standard for arsenic of 50 µg L-1. This may place many people at risk 468 
of developing arsenic induced adverse health effects with persistent exposure. Our 469 
findings support an association between skin lesions and a higher intake of arsenic 470 
concentrations beyond the WHO provisional guideline value for arsenic in drinking 471 
water (10 ȝJ/í1).  472 
20 
 
6. Ethical Approval 473 
The study was approved by the National Bioethics Committee of Pakistan and 474 
University of Leeds Research Ethics Committee. 475 
 476 
 477 
References 478 
Agency for Toxic Substances and Disease Registry. 2007. Toxicological profile for 479 
arsenic. Atlanta, GA: U.S. Department of Health and Human Services. 480 
Available: http://www.atsdr.cdc.gov/toxpro files/tp2.pdf [Accessed May 12, 481 
2015]. 482 
Ahmed, M., Fatmi, Z. & Ali, A. 2014. Correlation of arsenic exposure through drinking 483 
groundwater and urinary arsenic excretion among adults in pakistan. J 484 
Environ Health, 76, 48-54,  485 
Ahsan, H., Chen, Y., Kibriya, M. G., Slavkovich, V., Parvez, F., Jasmine, F., Gamble, 486 
M. V. & Graziano, J. H. 2007. Arsenic metabolism, genetic susceptibility, and 487 
risk of premalignant skin lesions in bangladesh. Cancer Epidemiol Biomarkers 488 
Prev, 16.^10.1158/1055-9965.epi-06-0676 489 
Ahsan, H., Chen, Y., Parvez, F., Zablotska, L., Argos, M., Hussain, I., Momotaj, H., 490 
Levy, D., Cheng, Z., Slavkovich, V., Van Geen, A., Howe, G. R. & Graziano, 491 
J. H. 2006. Arsenic exposure from drinking water and risk of premalignant 492 
skin lesions in bangladesh: Baseline results from the health effects of arsenic 493 
longitudinal study. Am J Epidemiol, 163, 1138-1148.^10.1093/aje/kwj154 494 
Ahsan, H., Perrin, M., Rahman, A., Parvez, F., Stute, M., Zheng, Y., Milton, A. H., 495 
Brandt-Rauf, P., Van Geen, A. & Graziano, J. 2000. Associations between 496 
drinking water and urinary arsenic levels and skin lesions in bangladesh. J 497 
Occup Environ Med, 42, 1195-1201,  498 
Argos, M., Kalra, T., Pierce, B. L., Chen, Y., Parvez, F., Islam, T., Ahmed, A., Hasan, 499 
R., Hasan, K., Sarwar, G., Levy, D., Slavkovich, V., Graziano, J. H., Rathouz, 500 
P. J. & Ahsan, H. 2011. A prospective study of arsenic exposure from drinking 501 
water and incidence of skin lesions in bangladesh. Am J Epidemiol, 174, 185-502 
194.^10.1093/aje/kwr062 503 
Barr, D. B., Wilder, L. C., Caudill, S. P., Gonzalez, A. J., Needham, L. L. & Pirkle, J. 504 
L. 2005. Urinary creatinine concentrations in the u.S. Population: Implications 505 
for urinary biologic monitoring measurements. Environ Health Perspect, 113, 506 
192-200,  507 
Bonsnes, R. W. & Taussky, H. H. 1945. On the colorimetric determination of 508 
creatinine by the jaffe reaction. Journal of Biological Chemistry, 158,  509 
Chen, Y., Wu, F., Graziano, J. H., Parvez, F., Liu, M., Paul, R. R., Shaheen, I., 510 
Sarwar, G., Ahmed, A., Islam, T., Slavkovich, V., Rundek, T., Demmer, R. T., 511 
Desvarieux, M. & Ahsan, H. 2013. Arsenic exposure from drinking water, 512 
arsenic methylation capacity, and carotid intima-media thickness in 513 
bangladesh. Am J Epidemiol, 178, 372-381.^10.1093/aje/kwt001 514 
21 
 
Chen, Y. C., Su, H. J., Guo, Y. L., Hsueh, Y. M., Smith, T. J., Ryan, L. M., Lee, M. S. 515 
& Christiani, D. C. 2003. Arsenic methylation and bladder cancer risk in 516 
taiwan. Cancer Causes Control, 14, 303-310,  517 
Fatmi, Z., Abbasi, I. N., Ahmed, M., Kazi, A. & Kayama, F. 2013. Burden of skin 518 
lesions of arsenicosis at higher exposure through groundwater of taluka 519 
gambat district khairpur, pakistan: A cross-sectional survey. Environ 520 
Geochem Health, 35, 341-346.^DOI: 10.1007/s10653-012-9498-3 521 
Fatmi, Z., Azam, I., Ahmed, F., Kazi, A., Gill, A. B., Kadir, M. M., Ahmed, M., Ara, N. 522 
& Janjua, N. Z. 2009. Health burden of skin lesions at low arsenic exposure 523 
through groundwater in pakistan. Is river the source? Environ Res, 109, 575-524 
581.^DOI: 10.1016/j.envres.2009.04.002 525 
Gamble, M. V., Liu, X., Ahsan, H., Pilsner, R., Ilievski, V., Slavkovich, V., Parvez, F., 526 
Levy, D., Factor-Litvak, P. & Graziano, J. H. 2005. Folate, homocysteine, and 527 
arsenic metabolism in arsenic-exposed individuals in bangladesh. Environ 528 
Health Perspect, 113.^10.1289/ehp.8084 529 
Guha Mazumder, D. N., Haque, R., Ghosh, N., De, B. K., Santra, A., Chakraborty, D. 530 
& Smith, A. H. 1998. Arsenic levels in drinking water and the prevalence of 531 
skin lesions in west bengal, india. Int J Epidemiol, 27, 871-877,  532 
Guo, X., Fujino, Y., Ye, X., Liu, J., Yoshimura, T. & Japan Inner Mongolia Arsenic 533 
Pollution Study, G. 2006. Association between multi-level inorganic arsenic 534 
exposure from drinking water and skin lesions in china. International Journal 535 
of Environmental Research and Public Health, 3, 262-267,  536 
Haque, R., Mazumder, D. N., Samanta, S., Ghosh, N., Kalman, D., Smith, M. M., 537 
Mitra, S., Santra, A., Lahiri, S., Das, S., De, B. K. & Smith, A. H. 2003. Arsenic 538 
in drinking water and skin lesions: Dose-response data from west bengal, 539 
india. Epidemiology, 14, 174-182.^10.1097/01.ede.0000040361.55051.54 540 
Hirano, S., Cui, X., Li, S., Kanno, S., Kobayashi, Y., Hayakawa, T. & Shraim, A. 541 
2003. Difference in uptake and toxicity of trivalent and pentavalent inorganic 542 
arsenic in rat heart microvessel endothelial cells. Arch Toxicol, 77, 305-543 
312.^10.1007/s00204-003-0447-x 544 
Hong, Y.-S., Song, K.-H. & Chung, J.-Y. 2014. Health effects of chronic arsenic 545 
exposure. Journal of Preventive Medicine and Public Health, 47, 245-546 
252.^10.3961/jpmph.14.035 547 
Hsieh, R.-L., Huang, Y.-L., Shiue, H.-S., Huang, S.-R., Lin, M.-I., Mu, S.-C., Chung, 548 
C.-J. & Hsueh, Y.-M. 2014. Arsenic methylation capacity and developmental 549 
delay in preschool children in taiwan. International Journal of Hygiene and 550 
Environmental Health, 217, 678-551 
686.^https://doi.org/10.1016/j.i jheh.2014.02.004 552 
Hsueh, Y.-M., Chen, W.-J., Lee, C.-Y., Chien, S.-N., Shiue, H.-S., Huang, S.-R., Lin, 553 
M.-I., Mu, S.-C. & Hsieh, R.-L. 2016. Association of arsenic methylation 554 
capacity with developmental delays and health status in children: A 555 
prospective case±control trial. Scientific Reports, 6, 556 
37287.^10.1038/srep37287 557 
International Agency for Research on Cancer 2004. Summaries & evaluations: 558 
Arsenic in drinking-water (group 1). In: CANCER, I. A. F. R. O. (ed.) IARC 559 
22 
 
Monographs on the Evaluation of Carcinogenic Risk to Humans, Vol. 84. 560 
IARC, Lyon. 561 
International Agency for Research on Cancer. 2012. Arsenic, metals, fibres and 562 
dusts,. 100C. Available: 563 
http://monographs.iarc.fr/ENG/Monographs/vol100C/mono100C.pdf.pp:41-44 564 
[Accessed March 3, 2017]. 565 
Jakariya, M. D., Rahman, M., Chowdhury, A. M. R., Rahman, M., Yunus, M. D., 566 
Bhiuya, A., Wahed, M. A., Bhattacharya, P., Jacks, G., Vahter, M. & Persson, 567 
L. a. K. 2005. Sustainable safe water options in bangladesh: Experiences 568 
from the arsenic project at matlab (asmat). 319-330 569 
Kile, M. L., Hoffman, E., Rodrigues, E. G., Breton, C. V., Quamruzzaman, Q., 570 
Rahman, M., Mahiuddin, G., Hsueh, Y. M. & Christiani, D. C. 2011. A 571 
pathway-based analysis of urinary arsenic metabolites and skin lesions. Am J 572 
Epidemiol, 173, 778-786.^10.1093/aje/kwq427 573 
Li, X., Li, B., Xu, Y., Wang, Y., Jin, Y., Itoh, T., Yoshida, T. & Sun, G. 2011. Arsenic 574 
methylation capacity and its correlation with skin lesions induced by 575 
contaminated drinking water consumption in residents of chronic arsenicosis 576 
area. Environ Toxicol, 26, 118-123.^10.1002/tox.20535 577 
Li, Y., Wang, D., Li, X., Zheng, Q. & Sun, G. 2015. A potential synergy between 578 
incomplete arsenic methylation capacity and demographic characteristics on 579 
the risk of hypertension: Findings from a cross-sectional study in an arsenic-580 
endemic area of inner mongolia, china. Int J Environ Res Public Health, 12, 581 
3615-3632.^10.3390/ijerph120403615 582 
Lien, H. C., Tsai, T. F., Lee, Y. Y. & Hsiao, C. H. 1999. Merkel cell carcinoma and 583 
chronic arsenicism. J Am Acad Dermatol, 41, 641-643,  584 
Lindberg, A. L., Rahman, M., Persson, L. A. & Vahter, M. 2008. The risk of arsenic 585 
induced skin lesions in bangladeshi men and women is affected by arsenic 586 
metabolism and the age at first exposure. Toxicol Appl Pharmacol, 587 
230.^10.1016/j.taap.2008.02.001 588 
Lindberg, A. L., Sohel, N., Rahman, M., Persson, L. A. & Vahter, M. 2010. Impact of 589 
smoking and chewing tobacco on arsenic-induced skin lesions. Environ 590 
Health Perspect, 118, 533-538.^10.1289/ehp.0900728 591 
Mendez, W. M., Jr., Eftim, S., Cohen, J., Warren, I., Cowden, J., Lee, J. S. & Sams, 592 
R. 2017. Relationships between arsenic concentrations in drinking water and 593 
lung and bladder cancer incidence in u.S. Counties. J Expo Sci Environ 594 
Epidemiol, 27, 235-243.^10.1038/jes.2016.58 595 
Mitra, S. R., Mazumder, D. N. G., Basu, A., Block, G., Haque, R., Samanta, S., 596 
Ghosh, N., Hira Smith, M. M., Von Ehrenstein, O. S. & Smith, A. H. 2004. 597 
Nutritional factors and susceptibility to arsenic-caused skin lesions in west 598 
bengal, india. Environmental Health Perspectives, 112, 1104-599 
1109.^10.1289/ehp.6841 600 
National Research Council. 2001. Arsenic in drinking water : 2001 update. 601 
Washington, DC. Available: https://www.nap.edu/catalog/10194/arsenic-in-602 
drinking-water-2001-update [Accessed September 29, 2015]. 603 
23 
 
Petrick, J. S., Jagadish, B., Mash, E. A. & Aposhian, H. V. 2001. 604 
Monomethylarsonous acid (mma(iii)) and arsenite: Ld(50) in hamsters and in 605 
vitro inhibition of pyruvate dehydrogenase. Chem Res Toxicol, 14, 651-656,  606 
Rahman, M., Vahter, M., Sohel, N., Yunus, M., Wahed, M. A., Streatfield, P. K., 607 
Ekström, E.-C. & Persson, L. Å. 2006. Arsenic exposure and age- and sex-608 
specific risk for skin lesions: A population-based case±referent study in 609 
bangladesh. Environmental Health Perspectives, 114, 1847-610 
1852.^10.1289/ehp.9207 611 
Rasheed, H., Kay, P., Slack, R., Gong, Y. Y. & Carter, A. 2017a. Human exposure 612 
assessment of different arsenic species in household water sources in a high 613 
risk arsenic area. Sci Total Environ, 584-585, 631-614 
641.^10.1016/j.scitotenv.2017.01.089 615 
Rasheed, H., Slack, R., Kay, P. & Gong, Y. Y. 2017b. Refinement of arsenic 616 
attributable health risks in rural pakistan using population specific dietary 617 
intake values. Environment International, 99, 331-618 
342.^https://doi.org/10.1016/j.envint.2016.12.018 619 
Steinmaus, C., Bates, M. N., Yuan, Y., Kalman, D., Atallah, R., Rey, O. A., Biggs, M. 620 
L., Hopenhayn, C., Moore, L. E., Hoang, B. K. & Smith, A. H. 2006. Arsenic 621 
methylation and bladder cancer risk in case-control studies in argentina and 622 
the united states. J Occup Environ Med, 48, 478-623 
488.^10.1097/01.jom.0000200982.28276.70 624 
Sun, G. 2004. Arsenic contamination and arsenicosis in china. Toxicol Appl 625 
Pharmacol, 198, 268-271.^10.1016/j.taap.2003.10.017 626 
Sun, G., Xu, Y., Li, X., Jin, Y., Li, B. & Sun, X. 2007. Urinary arsenic metabolites in 627 
children and adults exposed to arsenic in drinking water in inner mongolia, 628 
china. Environ Health Perspect, 115, 648-652.^10.1289/ehp.9271 629 
Sun Guifan, Liu Jiayi, T.V. Luong, Sun Dianjun & Liying, W. 2004. Endemic 630 
arsenicosis: A clinical diagnostic manual with photo illustrations. UNICEF and 631 
the Ministry of Health, People's Republic of China. Available: 632 
https://www.unicef.org/eapro/Endemic_arsenicosis.pdf [Accessed May 22, 633 
2014]. 634 
U.S. Environmental Protection Agency 1996. Determination of trace elements in 635 
ambient waters by inductively coupled plasma ² mass spectrometry method 636 
1638. U.S. Environmental Protection Agency, Office of Water, Engineering 637 
and Analysis Division (4303), 401 M Street S.W. Washington, D.C. 20460. 638 
U.S. Environmental Protection Agency. 2008. Determination of trace elements in 639 
waters and wastes by inductively coupled plasma ± mass spectrometry. 640 
Method 200.8 (modified)Environmental Monitoring Systems Laboratory Office 641 
of Research and Development: USEPA Cincinnati, Ohio 45268. Available: 642 
https://www.epa.gov/sites/production/files/2015-08/documents/method_200-643 
8_rev_5-4_1994.pdf. [Accessed February 21, 2014]. 644 
Vahter, M. 1999. Methylation of inorganic arsenic in different mammalian species 645 
and population groups. Sci Prog, 82 ( Pt 1), 69-88,  646 
Vahter, M. 2002. Mechanisms of arsenic biotransformation. Toxicology, 181-182, 647 
211-217,  648 
24 
 
Vahter, M., Concha, G., Nermell, B., Nilsson, R., Dulout, F. & Natarajan, A. T. 1995. 649 
A unique metabolism of inorganic arsenic in native andean women. Eur J 650 
Pharmacol, 293, 455-462,  651 
Valenzuela, O. L., Drobna, Z., Hernandez-Castellanos, E., Sanchez-Pena, L. C., 652 
Garcia-Vargas, G. G., Borja-Aburto, V. H., Styblo, M. & Del Razo, L. M. 2009. 653 
Association of as3mt polymorphisms and the risk of premalignant arsenic skin 654 
lesions. Toxicol Appl Pharmacol, 239, 200-207.^10.1016/j.taap.2009.06.007 655 
Wei, Q. 1998. Effect of aging on DNA repair and skin carcinogenesis: A minireview 656 
of population-based studies. J Investig Dermatol Symp Proc, 3, 19-22,  657 
Yang, L., Chai, Y., Yu, J., Wei, B., Xia, Y., Wu, K., Gao, J., Guo, Z. & Cui, N. 2017. 658 
Associations of arsenic metabolites, methylation capacity, and skin lesions 659 
caused by chronic exposure to high arsenic in tube well water. Environ 660 
Toxicol, 32, 28-36.^10.1002/tox.22209 661 
Zablotska, L. B., Chen, Y., Graziano, J. H., Parvez, F., Van Geen, A., Howe, G. R. & 662 
Ahsan, H. 2008. Protective effects of b vitamins and antioxidants on the risk of 663 
arsenic-related skin lesions in bangladesh. Environ Health Perspect, 116, 664 
1056-1062.^10.1289/ehp.10707 665 
Zhang, Q., Li, Y., Liu, J., Wang, D., Zheng, Q. & Sun, G. 2014. Differences of urinary 666 
arsenic metabolites and methylation capacity between individuals with and 667 
without skin lesions in inner mongolia, northern china. Int J Environ Res 668 
Public Health, 11, 7319-7332.^10.3390/ijerph110707319 669 
 670 
671 
25 
 
  Table 1: The baseline characteristics of the study participants  672 
Characteristics 
n Overall 
(Mean±SD) 
with skin 
lesions 
(Mean±SD) 
(n=66) 
Without skin 
lesions 
(Mean±SD) 
(n=332)a 
p-value 
Age of participants (years) 398 35.74±16.99 39.92±15.19 34.91±17.23  0.001*** 
Body w eight (kg) 398 56.66±19.92 64.45±15.43 55.11±20.37 0.0005*** 
Daily total w ater intake (L 
person-1 day-1) 
398 3.47±0.955 3.98±0.97 3.38±0.92 0.0005*** 
Daily arsenic intake from 
w ater (mg day-1) 
398 0.78±2.01 3.23±3.57 0.32±0.98 0.0005*** 
tAs conc. in household 
water sources (µg L-1) 
  
 
  
Chak-46/12-L 121 62.28±39.42 113.38 ± 47.82 53.34 ± 30.09 - 
Chak-48/12-I 54 275.30±335.97 497.51 ± 433.07 164.17 ± 204.30 - 
Chak 49/12-l 75 54.57±26.18 81.99 ± 13.37 51.75 ± 25.58 - 
Basti Balochan 44 24.88±0.68 NA 24.88 ± 6.81 - 
Badarpur 34 1605.64±882.51 1874.26 ± 776.88 
1043.98 ± 854.0 - 
Basti Kotla Arab 70 14.784±13.96 NA 14.784 ± 13.95 - 
Overall tAs 398 209.08±519.20 828.46±934.28 85.96±245.38 0.0005*** 
Urinary arsenic concentration (ȝJJ-1 Cr) 
Urinary tAs   395 407.66±659.34 760.48±883.81 336.87±580.81 0.0005*** 
iAs 395 59.52±131.45 133.40±242.48 44.24±86.48 0.0005*** 
MMA 385 47.59±71.60 106.38±135.04 35.43±39.97 0.0005*** 
DMA 385 255.19±301.20 464.70±518.34 211.85±208.90 0.008** 
Urinary arsenic proportions and methylation indices  
iAs% 395 15.05±8.99 17.75±9.66 14.50±8.77 0.001*** 
MMA% 385 12.65±5.13 15.26±6.31 12.11±4.68 0.0005*** 
DMA% 385 72.29±11.28 66.99±13.59 73.39±10.44 0.006** 
PMI 385 0.85±0.09 0.82±0.10 0.86±0.09 0.032* 
SMI 385 0.85±0.08 0.81±0.11 0.86±0.07 0.003** 
    
an varies for results of urinary arsenic metabolites and methylation indices.  673 
    SD: Standard deviation 674 
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 677 
Table 2. The ORs for skin lesions by levels of demographic and lifestyle 678 
factors 679 
Co-variates 
Total 
number of 
participants  
Without 
skin lesion 
(n=332) 
With skin 
lesion 
(n=66) 
Prevalence 
% p-value OR (95% CI) (n=398) 
n n n 
Sex 
female   149 132 17 11.4 0.034* 1.00 (ref) 
male   249 200 49 19.7 1.90 (1.05, 3.45) 
Age 
\HDUV 66 62 4 6 0.018* 1.00 (ref) 
>16 years 332 270 62 18.67 3.56 (1.25,10.152) 
 tAs in household water sources (µg L -1)  
10-50 147 146 1 0.68 
  
 p<0.001*** 
  
1.00 (ref) 
50-100 123 106 17 13.82 23.4 (3.06,178.68) 
>100 80 32 48 60 219.0 (29.142,1645.7) 
Daily arsenic intake (mg day-1) 
Q1:0.001-0.070 99 99 0 0 
p<0.001*** 
- 
Q2:0.071-0.160 100 99 1 1 1.00 (ref) 
Q3:0.162-0.330 99 90 9 9.1 10.01 (1.24,80.59) 
Q4:0.332-11.773 100 44 56 56 126.0 (16.89,939.46) 
Villages 
Chak 49/12-l 75 68 7 9.3 
p<0.001*** 
1.00 (ref) 
Chak-46/12-L 121 107 18 14.9 1.70 (0.67, 4.28) 
Chak-48/12-I 54 34 18 33.3 4.86 (1.86, 12.71) 
Badarpur 34 12 23 67.7 20.31 (7.04, 58.57) 
Basti Balochan 44 44 0 0 0 
Basti Kotla Arab 70 70 0 0 0 
Body weight (kg) 
NJ 67 63 4 6 0.016* 1.00 (ref) 
> 35 kg 331 269 62 18.7 3.63 (1.273,10.35) 
Occupation 
Labour non-
Intensive 149 136 13 8.7 0.002** 1.00 (ref) 
Labour intensive 249 196 53 21.3 2.83 (1.48,5.39) 
CI, Conf idence interv al 680 
Q: Quartile 681 
S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Table 3. The logistic regression analysis of ORs, unadjusted and adjusteda, for 685 
skin lesions risk by level of urinary arsenic metabolites 686 
Urinary arsenic exposure 
measures (quartiles) 
With 
skin 
lesions 
(n=66) 
Without 
skin 
lesion 
(n=332) 
Unadjusted OR 
(95% CI) p-Value 
Adjusted ORa   
(95% CI) p-value 
Urinary 
W$VȝJJ-
1
 Cr) b 
7.78-123.42 4 94 1.00 (ref) - 1.00 (ref) S 
123.58-246.94 11 88 2.94 (0.90-9.57) 0.074 3.14 (0.96-10.31) 0.059 
247.19-426.67 21 78 6.33 (2.08-19.21) 0.001*** 6.35 (2.08-19.44) 0.001** 
441.12-8743.59 30 72 9.79 (3.30-29.05) 0.0005*** 13.07 (4.30-39.68) S 
Urinary 
L$VȝJJ-
1
 Cr) b 
 0.14-13.796 9 87 1.00 (ref)   1.00 (ref) S0.001*** 
 13.81-28.58 8 88 0.88 (0.32-2.38) 0.8 1.00 (0.37-2.75) 0.993 
 28.66-56.58 14 82 1.65 (0.68-4.02) 0.27 1.81 (0.74-4.47) 0.195 
 58.24-1411.11 35 75 4.51(2.04-9.99) 0.0005*** 5.61 (2.48-12.70) S 
Urinary 
00$ȝJ
g-1 Cr) c 
 0.08-10.89 9 87 1.00 (ref)   1.00 (ref) S 
 10.9-27.03 6 90 0.64 (0.22-1.89) 0.423 0.76 (0.26-2.24) 0.617 
 27.32-54.44 16 80 1.93 (0.81-4.62) 0.138 2.09 (0.87-5.05) 0.101 
 54.49-615.31 35 75 4.51 (2.04-9.99) 0.0005*** 5.83 (2.57-13.24) S 0.001*** 
Urinary 
'0$ ȝJ
g-1 Cr) c 
 0.077-90.90 8 88 1.00 (ref)   1.00 (ref) S 
 91.48-164.94 10 86 1.28 (0.48-3.39) 0.621 1.38 (0.52-3.70) 0.520 
 165.42-302.10 19 77 2.71 (1.12-6.55) 0.026* 2.78 (1.14-6.77) 0.024* 
 307.80-2353.5 29 81 3.94 (1.70-9.11) 0.001*** 4.93 (2.08-11.64) S 
CI, confidence interval  687 
Cut off points w ere determined by quartiles of urinary arsenic metabolites of overall study participants. 688 
S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 689 
a
 ORs w ere adjusted by participant¶VRFFXSDWLRQ 690 
b n=395, 691 
 
c n=385 692 
  693 
28 
 
Table 4. The logistic regression analysis of the ORs unadjusted and adjusteda, 694 
for skin lesions risk in relation to urinary arsenic methylation indices 695 
  696 
Urinary arsenic 
exposure measures 
(quartiles) 
With 
skin 
lesions 
(n=66) 
Without 
skin 
lesion 
(n=329) 
Unadjusted 
OR (95% CI) p-value 
Adjusted ORa 
(95% CI) p-value 
%iAs 
2.47-10.08 11 85 1.00 (ref) 
  
1.00 (ref) 0.012* 
10.14-12.98 9 87 0.80 (0.32-2.03) 0.637 0.80 (0.31-2.06) 0.648 
12.99-17.0 19 77 1.91 (0.85-4.26) 0.116 1.79 (0.79-4.05) 0.160 
17.01-75.28 27 83 2.51 (1.17-5.39) 0.018* 2.65 (1.22-5.75) 0.014* 
MMA%b 
0.63-8.97 7 89 1.00 (ref) 
  
1.00 (ref) 0.002** 
9.01-11.98 13 83 1.99 (0.76-5.23) 0.162 2.20 (0.83-5.84) 0.113 
11.98-15.90 16 80 2.54 (1.00-6.50) 0.051 2.72 (1.05-7.01) 0.039* 
15.92-42.62 30 80 4.77 (1.98-11.45) 0.0005*** 5.06 (2.09-12.27) 
S 
DMA% b 
8.5-68.51 28 69 1.00 (ref)   1.00 (ref) S 
68.57-73.93 20 75 0.66 (0.34-1.27) 0.213 0.64 (0.33-1.26) 0.201 
73.98-79.02 9 87 0.26 (0.11-0.58) 0.001*** 0.25 (0.11-0.56) 0.001** 
79.08,91.57 9 101 0.22 (0.10-0.49) 0.0005*** 0.22 (0.10-0.50) S 
PMI b 
0.247-0.829 27 69 1.00 (ref) 
  
1.00 (ref) 0.001*** 
0.830-0.870 19 78 0.62 (0.32-1.22) 0.166 0.56 (0.28-1.12) 0.099 
0.870-0.899 9 87 0.26 (0.12-0.60) 0.001*** 0.25 (0.11-0.58) 0.001*** 
0.899-0.975 11 98 0.29 (0.13-0.62) 0.001*** 0.28 (0.13-0.60) 0.001*** 
SMI b 
0.293-0.814 30 67 1.00 (ref)   1.00 (ref) S 
0.814-0.856 15 80 0.42 (0.21-0.84) 0.015* 0.43 (0.21-0.88) 0.020* 
0.856-0.894 13 83 0.35 (0.17-0.72) 0.005** 0.34 (0.16-0.71) 0.004** 
0.895-0.976 8 102 0.18 (0.08-0.41) 0.0005*** 0.17 (0.07-0.40) S 
CI, confidence interval 697 
Cut off points of urinary were determined by quartiles of overall study participants.  698 
S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 699 
a
 $GMXVWHGE\YLOODJHU¶VRFFXSDWLRQ 700 
b n=385 701 
  702 
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 736 
  737 
 738 
398 participants having >6 months of 
arsenic exposure through water 
318 participants with no 
skin leisons 
80 participants examined 
by physician 
14 participants with no 
confirmed skin leisons 
 
80 participants initially 
identified with skin leisons 
Confirmation of 66 participants  
with skin leisons 
Spotty white 
appearance 
Rain-drop like 
pigmentation/ 
depigmentation, 
diffused 
hyperpigmentation  
Symptoms of both 
Raised, punctuate, 0.4-
1 cm or bigger warts 
specifically on palms 
and soles 
Hypopigmentation Hyperpigmentation Hypopigmentation/ hyperpigmentation 
Keratosis/ 
hyperkeratosis  
Arsenic induced skin lesions 
(Yes/No) 
Figure-1: Steps involved in screening of participants with arsenic-induced skin leisons 
30 
 
 739 
  
 
 
a b c 
   
d e f 
Figure-2(a±f): Different types of arsenic-specific skin lesions  740 
(a) Keratosis on sole (b) Keratosis on palm (c) Hypopigmentation on hand (d) Hyperpigmentation on palms (e) 741 
Melanosis on trunk (f) Hyperkeratosis  on lower limb.  742 
  743 
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 745 
Figure-3: Households showing tAs concentration in ground water sources and inter-individual 746 
variability for arsenic induced skin lesions 747 
 748 
